COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL

被引：3

作者：

Pititto, L. ^{[1
]}

Neslusan, C. ^{[2
]}

Teschemaker, A. R. ^{[2
]}

Johansen, P. ^{[3
]}

Willis, M. ^{[3
]}

Asano, E. ^{[1
]}

Puig, A. ^{[4
]}

机构：

[1] Janssen Cilag Farmaceut Ltda, Sao Paulo, Brazil

[2] Janssen Global Serv LLC, Raritan, NJ USA

[3] Swedish Inst Hlth Econ, Lund, Sweden

[4] Johnson & Johnson Int, New Brunswick, NJ USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 07期

关键词：

D O I：

10.1016/j.jval.2015.09.510

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB14

引用

下载

页码：A864 / A864

页数：1

共 50 条

[1] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
Martin, Silas
Neslusan, Cheryl
Vo, Lien
Teschemaker, Anna
Johansen, Pierre
Willis, Michael
DIABETES, 2014, 63 : A310 - A310
[2] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
Seufert, Jochen
Aggarwal, Naresh
Bailey, Robert
Cao, Anjun
Fung, Albert
Pfeifer, Michael
Alba, Maria
Rodbard, Helena W.
DIABETES, 2016, 65 : A308 - A308
[3] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
Neslusan, C.
Teschemaker, A.
Martin, S.
Willis, M.
Johansen, P.
VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
[4] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
Thompson, G.
Schroeder, M.
Neslusan, C.
Willis, M.
Johansen, P.
Teschemaker, A.
DIABETOLOGIA, 2014, 57 : S330 - S330
[5] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS AN AD-ON TO METFORMIN OR METFORMIN PLUS SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
Nielsen, A. T.
Pitcher, A.
Lovato, E.
Schubert, A.
Hemels, M.
Neslusan, C.
Gonzalez, B.
VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
[6] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND
Bacon, T.
Willis, M.
Johansen, P.
Neslusan, C.
Nuhoho, S.
Worbes-Cerezo, M.
VALUE IN HEALTH, 2014, 17 (07) : A346 - A346
[7] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
Lavalle Gonzalez, Fernando J.
Januszewicz, Andrzej
Davidson, Jaime
Qiu, Rose
Tong, Cindy
Meininger, Gary
DIABETES, 2013, 62 : A61 - A61
[8] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
Charokopou, M.
McEwan, P.
Lister, S.
Callan, L.
Bergenheim, K.
Tolley, K.
Postema, R.
Townsend, R.
Roudaut, M.
DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
[9] Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States
Neslusan, Cheryl
Martin, Silas
Teschemaker, Anna
Vo, Lien
Johansen, Pierre
Willis, Michael
DIABETES, 2014, 63 : A309 - A310
[10] IMPACT OF WEIGHT-RELATED UTILITIES ON THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
Sabapathy, S.
Neslusan, C.
Yoong, K.
Teschemaker, A. R.
Johansen, P.
Willis, M.
VALUE IN HEALTH, 2015, 18 (03) : A62 - A62

← 1 2 3 4 5 →